Molecular mechanisms of BCR::ABL1 in chronic myeloid leukaemia: From treatment-free remission to curative therapy
World Journal of Translational Medicine · 28.11.2026 · 12 (4)
DOI: 10.5528/wjtm.125122 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Translational Medicine, online erschienen am 28.11.2026. Verfasst von Temilola Oludunmomi Owojuyigbe und 1 weiteren Autor:innen. Die Arbeit nennt 93 Literaturangaben.
Abstract (Originalsprache)
Chronic myeloid leukaemia (CML) is a clonal malignancy defined by the dysregulated proliferation of granulocytic cells in the bone marrow. The aetiology is attributed to the chimeric oncogene BCR::ABL1 which is formed by the reciprocal translocation between chromosome 9 and 22, i.e. , (t9;22)(q34;q11). The oncoprotein product of the gene modulates leukaemogenesis through its intrinsic tyrosine kinase activity. The management of CML has improved significantly due to the discovery of tyrosine kinase inhibitors (TKIs), making treatment-free remission possible in selected patients with durable deep molecular remission (DMR). However, the therapeutic impact of TKIs has been impaired by the occurrence of mutations within the BCR::ABL1 kinase domain which confer resistance to TKIs. Also, leukaemic stem cells (LSCs) persist in a quiescent state within the bone marrow niche. Resistance mechanisms that are not related to BCR::ABL1 include drug efflux, microenvironmental influences, and epigenetic changes. Next‑generation sequencing and digital polymerase chain reaction (dPCR) enhance the detection of mutations and minimal residual disease, although real-time quantitative polymerase chain reaction remains the validated standard for routine monitoring. Kinase domain mutations are treated with second-generation TKIs (e.g. nilotinib), third‑generation TKIs (ponatinib) or allosteric inhibitors (asciminib). Emerging therapeutic strategies including combination regimens, immunotherapy, and precision medicine based on mutation profiling are currently being investigated. Most LSC- targeted and immunotherapeutic strategies remain in preclinical or early phase clinical trials. This review explores the molecular biology of BCR::ABL1 , evaluates resistance mechanisms, and establishes a conceptual framework which distinguishes functional remission and from biological cure.
Zitieren
APA
Owojuyigbe, T. O., & Durosinmi, M. A. (2026). Molecular mechanisms of BCR::ABL1 in chronic myeloid leukaemia: From treatment-free remission to curative therapy. World Journal of Translational Medicine, 12(4). https://doi.org/10.5528/wjtm.125122
Vancouver
Owojuyigbe TO, Durosinmi MA. Molecular mechanisms of BCR::ABL1 in chronic myeloid leukaemia: From treatment-free remission to curative therapy. World Journal of Translational Medicine. 2026;12(4). doi:10.5528/wjtm.125122
BibTeX
@article{Owojuyigbe2026,
author = {Owojuyigbe, Temilola Oludunmomi and Durosinmi, Muheez Alani},
title = {Molecular mechanisms of BCR::ABL1 in chronic myeloid leukaemia: From treatment-free remission to curative therapy},
journal = {World Journal of Translational Medicine},
year = {2026},
volume = {12},
number = {4},
doi = {10.5528/wjtm.125122}
}
EUVIMED